Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In Brief: E-Z-EM/Abbott

This article was originally published in The Gray Sheet

Executive Summary

E-Z-EM/Abbott: E-Z-EM's Enteric Products, Inc. subsidiary reaches marketing agreement with Abbott Laboratories covering serum and whole-blood versions of physician's office tests (co-developed by EPI and SmithKline Diagnostics) for the detection of H. Pylori. Under the agreement, Abbott will market the tests, which are manufactured by SKD, under the name FlexPack HP in China, India, other Asian countries, Eastern Europe, and parts of the Middle East and Africa. SKD also markets the tests under the name FlexSure HP in the U.S. and other "selected" regions. In return, EPI will receive revenue from: product sales directly to Abbott; royalties from product sales to Abbott by SKD and from SKD to distributors and end-users; and sales of EPI's HM-CAP antigen to SKD for use in the tests...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT006515

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel